Measurement uncertainty evaluation of an analytical procedure for determination of terbinafine hydrochloride in creams by HPLC and optimization strategies using Analytical Quality by Design

AQbD integrated high-performance thin layer chromatographic method for quantitative estimation of Tavaborole in the presence of its degradants and the matrix of nanostructured lipid carriers

BACKGROUND

Tavaborole (TAV), a benzoxaborole derivative, is an FDA-approved antifungal agent for treating onychomycosis, a common and persistent fungal infection of the toenails.

OBJECTIVE

This study aimed to develop a robust stability-indicating HPTLC method to determine TAV in nanostructured lipid carriers (NLC) using a comprehensive approach that includes risk assessment, and Analytical Quality by Design.

METHODS

The critical method parameters influencing the HPTLC results were screened using a Plackett-Burman screening design followed by its optimization using a central composite optimization design. The developed method was validated as per ICH recommendation.

RESULTS

Optimized method utilized pre-coated aluminum-backed HPTLC plates using 10 µL/band injection volume, and the plate was developed using an isocratic mobile phase consisting of toluene: ethyl acetate: formic acid (75:25:1%v/v/v) in twin trough chamber pre-saturated for 20 mins with vapors of 10 mL of mobile phase. The separated components were detected at a wavelength of 221 nm. The developed HPTLC method resulted in a retardation factor of 0.49 ± 0.04 for TAV. Validation results revealed the HPTLC method's specificity (peak purity ≥ 0.999), linearity over a concentration range of 2-10 μg/band, sensitivity (LOD 0.21 μg and LOQ 0.64 μg), accuracy (99.68 - 101.43%w/w), and precision (%RSD < 2.0).

CONCLUSION

The developed robust stability-indicating HPTLC method was successfully implemented for the sustainable testing of the TAV in the NLC formulations and stability testing.

Enhancing analytical development in the pharmaceutical industry: A DoE-QSRR model for virtual Method Operable Design Region assessment

Recently, the pharmaceutical industry has increasingly adopted the Analytical Quality by Design (AQbD) approach for analytical development. To facilitate AQbD approach implementation in the development of chromatographic methods for determining cephalosporin antibiotics, an in silico tool capable of performing virtual DoEs was developed enabling to obtain virtual operable regions of method. To this end, the drugs cephalexin, cefazolin, cefotaxime and ceftriaxone were analyzed using four experimental designs, deriving a DoE-QSRR model and employing Monte Carlo method. The DoE-QSRR model and virtual DoEs were validated using data not used in model's construction, obtaining coefficients of determination of 84.72 % for DoE-QSRR model and over 77 % for virtual DoEs. Virtual MODRs were constructed using data from the virtual DoEs. The virtual MODRs were validated by comparing them with experimental MODRs under various scenarios, with overlap areas reaching values exceeding 84 %. Therefore, the in silico tool was considered suitable for indicating analyte trends under different analytical conditions, being capable of performing virtual DoEs for cephalosporin drugs with sufficient assertiveness to guide analytical development and allow obtaining a MODR capable of providing results of adequate quality.

Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods - Uncertainties arising from sampling and analytical steps

Uniformity of dosage unit (UDU) test is widely used to assess the quality, safety, and effectiveness of dosage forms in unit doses. An increased variability of the amount of drug (API - Active Pharmaceutical Ingredient) in each dose unit may lead to low quality, unsafety, and ineffective medicines. The aim of this work was to evaluate the measurement uncertainty associated with the acceptance value (AV) using the Monte Carlo and Bootstrapping methods, as well as to estimate the risk of false decisions regarding compliance/non-compliance due to uncertainty. Haloperidon 5 mg tablets and ofloxacin 200 mg tablets were subject to content uniformity (CU) and weight variation (WV) tests, respectively. Measurement uncertainty evaluation of UDU tests considered both uncertainties arising from sampling analytical steps. Uncertainty values were quantified using Monte Carlo (sampling) or bootstrapping (resampling) methods. Confidence intervals at 95% confidence level (CI95%) for AV value obtained for haloperidol 5 mg tablets were found to between 8.1 and15.8 and between 8.1 and 16.9 for Boostrapping and Monte Carlo methods, respectively. There is an increased risk of false conformity assessment for haloperidol UDU test (6.5% and 12.1% risk values for Bootstrapping and Monte Carlo methods). Considering the ofloxacin 200 mg tablets, the CI95% for AV value were found to be between 4.0 and 11.3 and between 4.9 and 11.4 for Bootstrapping and Monte Carlo methods, respectively. Uncertainty arising from sampling and analytical steps were both relevant to the overall uncertainty of AV values. Measurement uncertainty evaluation provided relevant information to support conformity assessments with a reduced risk of false decision making.

Drilling into "Quality by Design" Approach for Analytical Methods

The need for consistency in analytical method development reinforces the dependence of pharmaceutical product development and manufacturing on robust analytical data. The Analytical Quality by Design (AQbD), akin to the product Quality by Design (QbD) endows a high degree of confidence to the method quality developed. AQbD involves the definition of the analytical target profile as starting point, followed by the identification of critical method variables and critical analytical attributes, supported on risk assessment and design of experiment tools for the establishment of a method operable design region and control strategy of the method. This systematic approach moves away from reactive troubleshooting to proactive failure reduction. The objective of this review is to highlight the elements of the AQbD framework and provide an overview of their implementation status in various analytical methods used in the pharmaceutical field. These methodologies include but are not limited to, high-performance liquid chromatography, UV-Vis spectrophotometry, capillary electrophoresis, supercritical fluid chromatography, and high-performance thin-layer chromatography. Finally, a critical appraisal is provided to highlight how regulators have encouraged AQbD principles application to boost the prevention of method failures and a better understanding of the method operable design region (MODR) and control strategy, ultimately resulting in cost-effectiveness and regulatory flexibility.

Development and optimization of a LC-MS/MS compatible method for quantification of losartan, hydrochlorothiazide and their impurities using AQbD approach and measurement uncertainty evaluation

The concept of Analytical Quality by Design (AQbD) comes as a more robust, economical, and scientifically based alternative for analytical development, to the detriment of OFAT (one factor at a time). This new understanding applicable to analytical development is recommended since regulatory flexibility can be achieved and ensure more reliable results throughout the life of the product. This new approach was applied to develop an analytical procedure indicative of stability for a pharmaceutical product of association of Losartan Potassium and Hydrochlorothiazide, considered a potential first line for the treatment of hypertension. The first stage of the analytical development consisted of defining analytical target profile (ATP), follow by a bibliographic survey of the physicochemical properties of the molecules in question to define an initial method. After defining the initial analytical conditions, statistical tools for design of experiments (DoE) were used for the screening and optimization steps. In the screening stage, the Plackett-Burman design was chosen, using 11 factors and 2 levels, through which it was possible to evaluate numerous variables and determine their significance in relation to the responses. Next, optimization was carried out with the experimental design of a central composite with 4 factors and 5 levels, which allowed modeling a complex response surface and evaluating the phenomena of interactions between the factors. Thus, the optimized analytical conditions were defined, considering a 0.3% formic acid gradient as eluent A and a mixture of acetonitrile and methanol (80:20) as eluent B, X-Bridge C18 chromatographic column (150 mm × 4 .6 mm × 3.5 μm), column temperature of 40°C, flow rate of 1.3 mL/min, injection volume of 10 μL. Through this methodology, it was possible to identify an unknown degradation product of Hydrochlorothiazide, formed by the reaction with lactose (excipient present in the drug formulation), proving that the method can be applicable both to DAD detectors and to spectrometry and mass detectors. It was also proven through the forced degradation study that the method is indicative of stability, in addition to being validated and robust for its purpose.

Analytical quality by design approach for the determination of imidazole in sildenafil API and its formulations using zwitterionic HILIC stationary phase

Herein, the development of a HILIC method for the determination of imidazole (Imp E) in sildenafil citrate API and its final formulations is reported. The main goal of this study was to develop a robust, application-specific HPLC method according to the Analytical Quality by Design principles for the analysis of the above impurity. After the risk assessment study, the high-risk method parameters were sequentially screened and optimized by using 2-level fractional factorial and Box-Behnken designs. The mathematical models were combined with the Monte-Carlo simulations to identify the Method Operable Design Region. The method was thoroughly validated between 25 % and 150 % of the target concentration limit of the imidazole using the total-error concept. The relative bias varied between 1.6 % and 5.6 % and the RSD values were lower than 5.8 % for repeatability and intermediate precision. The limit of detection and the lower limit of quantification were satisfactory and found to be 0.025 and 0.125 μg mL^-1 imidazole, respectively. The applicability of the proposed approach has been demonstrated in the analysis of several sildenafil citrate API batches and final products.

ECG Measurement Uncertainty Based on Monte Carlo Approach: An Effective Analysis for a Successful Cardiac Health Monitoring System

Measurement uncertainty is one of the widespread concepts applied in scientific works, particularly to estimate the accuracy of measurement results and to evaluate the conformity of products and processes. In this work, we propose a methodology to analyze the performance of measurement systems existing in the design phases, based on a probabilistic approach, by applying the Monte Carlo method (MCM). With this approach, it is feasible to identify the dominant contributing factors of imprecision in the evaluated system. In the design phase, this information can be used to identify where the most effective attention is required to improve the performance of equipment. This methodology was applied over a simulated electrocardiogram (ECG), for which a measurement uncertainty of the order of 3.54% of the measured value was estimated, with a confidence level of 95%. For this simulation, the ECG computational model was categorized into two modules: the preamplifier and the final stage. The outcomes of the analysis show that the preamplifier module had a greater influence on the measurement results over the final stage module, which indicates that interventions in the first module would promote more significant performance improvements in the system. Finally, it was identified that the main source of ECG measurement uncertainty is related to the measurand, focused towards the objective of better characterization of the metrological behavior of the measurements in the ECG.

A Highly Selective and Sensitive Nano-Silver sol Sensor for Hg2+ and Fe3+: Green Preparation and Mechanism

The development of highly selective and highly sensitive nanometer colorimetric chemical sensors is an urgent requirement in the immediate detection of heavy metal ions. In this work, silver-nanoparticle (Ag NPs)-based chemosensors were prepared by a simple and green method, in which the silver nitrate, carboxymethyl cellulose sodium (CMS) and Polyvinylpyrrolidone (PVP), and glucose are used as the silver source, double stabilizer and green reductant, respectively. The obtained colloidal CMS/PVP-Ag NPs showed a high dispersibility and stability, and creating a high selectivity and sensitivity to detect Hg2+ and Fe3+ with remarkable and rapid color variation. Low limits of detection (LOD) of 7.1 nM (0–20 μM) and 15.2 nM (20–100 μM) for Hg2+ and 3.6 nM for Fe3+ were achieved. More importantly, the CMS/PVP-Ag NPs has a high sensitivity even in a complex system with multiple heavy ions, the result of the practical ability to detect Hg2+ and Fe3+ in tap water and seawater reached a rational range of 98.33~104.2% (Hg2+) and 98.85~104.80% (Fe3+), indicating the great potential of the as-prepared nanocomposites colorimetric chemosensor for practical applications.